

20. Collecchi P, Passoni A, Rocchetta M, Gnesi E, Baldini E, Bevilacqua G. Cyclin-D1 expression in node-positive (N<sup>+</sup>) and node-negative (N<sup>-</sup>) infiltrating human mammary carcinomas. *Int J Cancer* 1999;84:139-44.
21. Michalides R, Hageman P, van Tinteren H, Houben L, Wientjens E, Klompmaker R, *et al.* A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. *Br J Cancer* 1996; 73:728-34.
22. Barbareschi M, Pelosio P, Caffo O, Buttitta F, Pellegrini S, Barbazza R, *et al.* Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathological characteristics and with retinoblastoma gene product, p53 and p21<sup>WAF1</sup> immunohistochemical expression. *Int J Cancer* 1997;74:171-4.
23. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, *et al.* Cyclin D1 expression in invasive breast cancer. correlations and prognostic value. *Am J Pathol* 1997;2:705-11.
24. Lipponen P, Ji H, Aaltomaa S, Syrjänen S, Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. *Int J Cancer* 1993;55: 51-6.
25. Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. *Hum Pathol* 1995;26:295-301.
26. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M, Syrjänen K. Expression of p53 protein has no independent prognostic value in breast cancer. *J Pathol* 1995;177: 225-32.
27. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. *Int J Cancer* 1998;41:178-83.
28. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P. p53, and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. *Am J Clin Pathol* 1992;98:408-18.
29. Bhargava V, Thor A, Deng G, Ljung B-M, Moore DH, Waldman F, *et al.* The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. *Mod Pathol* 1994;7:361-8.
30. MacGrogan G, Bonichon F, de Mascarel I, Trojani M, Durand M, Avril A, *et al.* Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. *Breast Cancer Res Treat* 1995;36:71-81.
31. Cunningham JM, Ingle JN, Jung SH, Cha SS, Wold LE, Farr G, *et al.* p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. *J Natl Cancer Inst* 1994;86:1871-3.
32. Seshadri R, Leong AS-Y, McCaul K, Fircgair FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. *Int J Cancer* 1996;69:135-41.
33. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell* 1997;88:323-31.
34. Haber DA. Splicing into senescence: the curious case of p16 and p19<sup>ARF</sup>. *Cell* 1997;91:555-8.
35. Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. Mechanisms of p16<sup>INK4A</sup> inactivation in non small-cell lung cancers. *Oncogene* 1998;16:497-504.
36. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, Chin L, *et al.* The *Ink4a* tumor suppressor gene product, p19<sup>Arf</sup>, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* 1998;92:713-23.
37. Lukas J, Aagaard L, Strauss M, Bartek J. Oncogenic aberrations of p16<sup>INK4/CDKN2</sup> and cyclin D1 cooperate to deregulate G<sub>1</sub> control. *Cancer Res* 1995;55:4818-23.
38. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. *Oncogene* 1997; 14:295-304.
39. An H-X, Beckmann MW, Reifenberger G, Bender HG, Niederacher D. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. *Am J Pathol* 1999;154:113-8.

## Book Review

**Lipp H-P, editor: *Anticancer Drug Toxicity: Prevention, Management, and Clinical Pharmacokinetics*, 558 pp, New York, Marcel Dekker, 1999 (\$195.00).**

This multiauthored book was edited by a German pharmacologist-pharmacist, aided by a dozen German and American oncologists-clinical pharmacologists. It consists of 13 chapters, most of which were written or co-authored by the editor himself, reflecting the fact that this book is an expanded and revised version of the editor's 1995 monograph on the same and related topics.

The first part of the book (~200 pages) deals with the basic pharmacokinetics of cytostatic drugs. As expected, this part contains formulas, graphs, and numerical data. Although these data are often presented in clinical context, this part will be read only by those seeking specific infor-

mation on a specific drug. In the second part of the book, devoted to organ-specific toxicity of most widely used cytotoxic drugs, the emphasis is more on clinical aspects of drug toxicity, and, accordingly, this part will be of more interest to clinicians, especially oncologists, clinical pharmacologists, and toxicologists. However, I think that it will have limited appeal to pathologists.

Each chapter is accompanied by references, the most recent of which are from 1997. Even so, the book is a valuable source of basic facts regarding common anticancer drugs. I see the book as being used primarily as a library reference, and I assume that it will be updated periodically in the future.

**Nevena Damjanov**  
*Temple University School of Medicine*  
*Philadelphia, Pennsylvania*